



SUPPLEMENTARY MATERIAL

Supplemental Fig. 1 Treatment schedule



CT, computed tomography; EOT, end of treatment; W, week


Supplemental Fig. 2 Platelet and white blood cell counts for patient 505 treated with BI 836826 100 mg during Cycles 1 and 2



Arrows represent days of administration

PLTCT, platelet count; WBC, white blood cell count

Supplemental Fig. 3 Comparison of individual and geometric mean $C_{\max, \text{norm}}$ values after the first infusion of BI 836826 over all dose groups from 3 mg to 200 mg (Caucasian and Korean patients combined)



gMean, geometric mean